| Literature DB >> 27297408 |
Fredrik Hessulf1, Johan Ljungberg2, Per-Anders Johansson2, Mats Lindgren2, Johan Engdahl2,3.
Abstract
BACKGROUND: Campylobacter spp. are among the most common bacterial causes of gastroenteritis world-wide and mostly follow a benign course. We report two cases of Campylobacter jejuni-associated perimyocarditis, the first two simultaneous cases published to date and the third and fourth cases over all in Sweden, and a review of the literature. CASEEntities:
Keywords: Campylobacter jejuni; High-sensitive Troponin T; Perimyocarditis; ST-elevation
Mesh:
Substances:
Year: 2016 PMID: 27297408 PMCID: PMC4907281 DOI: 10.1186/s12879-016-1635-7
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1Limb leads from 12-lead ECG from patient A showing typical generalized ST-segment elevation
Summary of baseline characteristics of all published case reports including patient A and patient B. n = 44 [4–6, 10–12, 14, 18, 22–49]a,b
| Characteristics | ||
|---|---|---|
| Age (years) | Mean | 29,4 |
| Max | 60 | |
| Min | 15 | |
| Myocarditis | All | 20(100) |
| Female | 0(0) | |
| Male | 20(100) | |
| Perimyocarditis | All | 19(100) |
| Female | 1(5) | |
| Male | 18(95) | |
| Pericarditis | All | 4(100) |
| Female | 3(75) | |
| Male | 1(25) |
aCampylobacter not identified to the species level (ref [26] and [28])
bMean age (43 years old) of the patient series which included one case of Campylobacter (ref [28])
Summary of the most recent case reports including case 1 (patient A)a and 2 (patient B)b. n = 14
| Sex/Age | Cardiac marker | ECG | Echo | MRI | Antibiotics | Outcome |
|---|---|---|---|---|---|---|
| M/24a | TnT 504 ng/L | ST-elevation | Normal, LVEF 60–65 % | No | Azithromycin | Full recovery |
| M/23b | TnT 128 ng/L | Normal | Normal incl LVEF | No | Azithromycin | Full recovery |
| M/60 [ | N/A | N/A | Pericard effusion | No | Ceftriaxone/Meropenem | Diarroea |
| M/43 [ | TnT 1.75 ng/ml | ST-elevation | Abn wall motion LVEF 68 % | Subepi/myocardial enhancement | Azithromycin | N/A |
| M/33 [ | TnI 18.6mcg/L | ST-elevation | LVEF 56 % | Increased signal subepi, dilated LV/RV | Roxithromycin | N/A |
| M/17 [ | TnI 16.8 ng/mL | ST-elevation | Normal | Subepicardial enhancement | Azithromycin | Full recovery |
| M/21 [ | TnI 15.6 ng/ml | Normal | Decreased LVEF | Subepi/myocardial enhancement | Azithromycin | Almost full rec |
| M/24 [ | TnI 8.9 mcg/L | ST-elevation | LVEF 40 % | Subepicardial enhancement | No | Full recovery |
| M/42 [ | TnI 11.6mcg/L | ST-elevation | LVEF 40 % | Subepicardial enhancement | Ciprofloxacin | Full recovery |
| M/21 [ | TnI 39.8mcg/L | ST-elevation | Normal inkc LVEF | No | Ciprofloxacin | Full recovery |
| M/21 [ | TnI 2.5mcg/L | ST-elevation | Normal incl LVEF | No | Yes(unknown kind) | Full recovery |
| M/24 [ | CK normal | Arrythmia | Decreased LVEF/peric effusion | No | Roxithromycin | N/A |
| M/19 [ | TnT 0.52 ng/mL | Strain | N/A | Yes | N/A | N/A |
| M/16 [ | TnT 1.7 ng/mL | ST-elevation | LVEF 45 % | No | Clarythromycin | Full recovery |
| M/17 [ | TnT 0.9 ng/mL | ST-elevation | Normal incl LVEF | Myocardial enhancement | Clarythromycin | Full recovery |
Fig. 2Pulsed-field gel electrophoresis according to the standardized Campynet protocol and using SmaI restriction enzyme. R: normalisation standard; M: molecular size marker; 36 and 37 show the banding patterns of the C. jejuni isolates from patient A and B, respectively